Core Laboratories N.V. (CLB) Reports In-Line Q2 EPS, Updates Guidance
Core Laboratories N.V. (NYSE: CLB) reported Q2 EPS of $1.32, in-line with the analyst estimate of $1.32. Revenue for the quarter came in at $263.1 million versus the consensus estimate of $267.24 million.
Core Laboratories N.V. sees Q3 2013 EPS of $1.33-1.34, versus the consensus of $1.34. Core Laboratories N.V. sees Q3 2013 revenue of $263-268 million, versus the consensus of $270.38 million.
Core Laboratories N.V. sees Q4 2013 EPS of $1.37-1.38, versus the consensus of $1.38. Core Laboratories N.V. sees Q4 2013 revenue of $268-270 million.
For earnings history and earnings-related data on Core Laboratories N.V. (CLB) click here.
Core Laboratories N.V. sees Q3 2013 EPS of $1.33-1.34, versus the consensus of $1.34. Core Laboratories N.V. sees Q3 2013 revenue of $263-268 million, versus the consensus of $270.38 million.
Core Laboratories N.V. sees Q4 2013 EPS of $1.37-1.38, versus the consensus of $1.38. Core Laboratories N.V. sees Q4 2013 revenue of $268-270 million.
For earnings history and earnings-related data on Core Laboratories N.V. (CLB) click here.